Elevated C-Reactive Protein is Associated with Cognitive Decline in Outpatients of a General Hospital: The Project in Sado for Total Health (PROST)

Dementia and Geriatric Cognitive Disorders Extra

Volumn 6, Issue 1, 2016, Pages 10-19

  Watanabe, Yumi ^a   Kitamura, Kaori ^a   Nakamura, Kazutoshi ^a   Sanpei, Kazuhiro ^b   Wakasugi, Minako ^a   Yokoseki, Akio ^b   Onodera, Osamu ^b   Ikeuchi, Takeshi ^c   Kuwano, Ryozo ^c   Momotsu, Takeshi ^b   Narita, Ichiei ^a   Endo, Naoto ^a  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^b Niigata University   (Japan)

^c NIIGATA UNIVERSITY   (Japan)

Author keywords

C reactive protein; Cognition in outpatients; Cross sectional studies; Elderly Japanese population; Epidemiology

Indexed keywords

C REACTIVE PROTEIN;

AGED; ALLELE; ARTICLE; BODY MASS; CEREBROVASCULAR ACCIDENT; CHRONIC INFLAMMATION; COGNITION; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; FEMALE; GENERAL HOSPITAL; HUMAN; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MENTAL DETERIORATION; MINI MENTAL STATE EXAMINATION; OUTPATIENT; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; SEX DIFFERENCE;

EID: 84973541944     PISSN: None     EISSN: 16645464     Source Type: Journal    
DOI: 10.1159/000442585     Document Type: Article

References (62)

1. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, Hall K, Hasegawa K, Hendrie H, Huang Y, Jorm A, Mathers C, Menezes PR, Rimmer E, Scazufca M; Alzheimer's Disease International: Global prevalence of dementia: a Delphi consensus study. Lancet 2005; 366: 2112-2117.
2. Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP: The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement 2013; 9: 63-75.e2.
3. Alzheimer's Association: 2013 Alzheimer's disease facts and figures. Alzheimers Dement 2013; 9: 208-245.
4. United Nations, Department of Economic and Social Affairs, Population Division: World Population Prospects: The 2015 Revision, Key Findings and Advance Tables. New York, United Nations, 2015.
5. Jack CR, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ: Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010; 9: 119-128.
6. Black S, Kushner I, Samols D: C-reactive protein. J Biol Chem 2004; 279: 48487-48490.
7. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC Jr, Taubert K, Tracy RP, Vinicor F; Centers for Disease Control and Prevention, American Heart Association: Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107: 499-511.
8. Rietzschel E, De Buyzere M: High-sensitive C-reactive protein: universal prognostic and causative biomarker in heart disease Biomark Med 2012; 6: 19-34.
9. Aiello AE, Nguyen H-OT, Haan MN: C-reactive protein mediates the effect of apolipoprotein E on cytomegalovirus infection. J Infect Dis 2008; 197: 34-41.
10. Amor S, Peferoen LAN, Vogel DYS, Breur M, van der Valk P, Baker D, van Noort JM: Inflammation in neurodegenerative diseases-an update. Immunology 2014; 142: 151-166.
11. Pimplikar SW: Neuroinflammation in Alzheimer's disease: from pathogenesis to a therapeutic target. J Clin Immunol 2014; 34(suppl 1):S64-S69.
12. Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, Jacobs AH, Wyss-Coray T, Vitorica J, Ransohoff RM, Herrup K, Frautschy SA, Finsen B, Brown GC, Verkhratsky A, Yamanaka K, Koistinaho J, Latz E, Halle A, Petzold GC, Town T, Morgan D, Shinohara ML, Perry VH, Holmes C, Bazan NG, Brooks DJ, Hunot S, Joseph B, Deigendesch N, Garaschuk O, Boddeke E, Dinarello CA, Breitner JC, Cole GM, Golenbock DT, Kummer MP: Neuroinflammation in Alzheimer's disease. Lancet Neurol 2015; 14: 388-405.
13. Koyama A, O'Brien J, Weuve J, Blacker D, Metti AL, Yaffe K: The role of peripheral inflammatory markers in dementia and Alzheimer's disease: a meta-analysis. J Gerontol A Biol Sci Med Sci 2013; 68: 433-440.
14. Yang J, Fan C, Pan L, Xie M, He Q, Li D, Wang S: C-reactive protein plays a marginal role in cognitive decline: a systematic review and meta-analysis. Int J Geriatr Psychiatry 2015; 30: 156-165.
15. Ge X, Xu X-Y, Feng C-H, Wang Y, Li Y-L, Feng B: Relationships among serum C-reactive protein, receptor for advanced glycation products, metabolic dysfunction, and cognitive impairments. BMC Neurol 2013; 13: 110.
16. Xu G, Zhou Z, Zhu W, Fan X, Liu X: Plasma C-reactive protein is related to cognitive deterioration and dementia in patients with mild cognitive impairment. J Neurol Sci 2009; 284: 77-80.
17. Chei C-L, Yamagishi K, Ikeda A, Noda H, Maruyama M, Cui R, Imano H, Kiyama M, Kitamura A, Asada T, Iso H; CIRCS Investigators: C-reactive protein levels and risk of disabling dementia with and without stroke in Japanese: the Circulatory Risk in Communities Study (CIRCS). Atherosclerosis 2014; 236: 438-443.
18. Yano Y, Matsuda S, Hatakeyama K, Sato Y, Imamura T, Shimada K, Kodama T, Kario K, Asada Y: Plasma Pentraxin 3, but not high-sensitivity C-reactive protein, is a useful inflammatory biomarker for predicting cognitive impairment in elderly hypertensive patients. J Gerontol A Biol Sci Med Sci 2010; 65: 547-552.
19. Kelley-Hedgepeth A, Lloyd-Jones DM, Colvin A, Matthews KA, Johnston J, Sowers MR, Sternfeld B, Pasternak RC, Chae CU; SWAN Investigators: Ethnic differences in C-reactive protein concentrations. Clin Chem 2008; 54: 1027-1037.
20. Morimoto Y, Conroy SM, Ollberding NJ, Kim Y, Lim U, Cooney RV, Franke AA, Wilkens LR, Hernandez BY, Goodman MT, Henderson BE, Kolonel LN, Le Marchand L, Maskarinec G: Ethnic differences in serum adipokine and C-reactive protein levels: the multiethnic cohort. Int J Obes (Lond) 2014; 38: 1416-1422.
21. Watanabe H, Goto S, Miyashita A, Maruyama H, Wakasugi M, Yokoseki A, Kuwano R, Narita I: Role of the p.E66Q variant of GLA in the progression of chronic kidney disease. Clin Exp Nephrol 2015; 19: 225-230.
22. Uchida Y, Uchida M, Machida S: Contributing factors to prevent dementia in community: participants' selfreport on prevention class of functional decline. Ann Gunma Health Sci 2009; 30: 1-8.
23. Myers GL, Rifai N, Tracy RP, Roberts WL, Alexander RW, Biasucci LM, Catravas JD, Cole TG, Cooper GR, Khan BV, Kimberly MM, Stein EA, Taubert KA, Warnick GR, Waymack PP; CDC; AHA: CDC/AHA workshop on markers of inflammation and cardiovascular disease: application to clinical and public health practice: report from the laboratory science discussion group. Circulation 2004; 110:e545-e549.
24. Folstein MF, Folstein SE, McHugh PR: 'Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198.
25. Kuwano R, Miyashita A, Arai H, Asada T, Imagawa M, Shoji M, Higuchi S, Urakami K, Kakita A, Takahashi H, Tsukie T, Toyabe S, Akazawa K, Kanazawa I, Ihara Y; Japanese Genetic Study Consortium for Alzheimer's Disease: Dynamin-binding protein gene on chromosome 10q is associated with late-onset Alzheimer's disease. Hum Mol Genet 2006; 15: 2170-2182.
26. Libby P, Theroux P: Pathophysiology of coronary artery disease. Circulation 2005; 111: 3481-3488.
27. Wellen KE, Hotamisligil GS: Inflammation, stress, and diabetes. J Clin Invest 2005; 115: 1111-1119.
28. Yasojima K, Schwab C, McGeer EG, McGeer PL: Human neurons generate C-reactive protein and amyloid P: upregulation in Alzheimer's disease. Brain Res 2000; 887: 80-89.
29. Arima H, Kubo M, Yonemoto K, Doi Y, Ninomiya T, Tanizaki Y, Hata J, Matsumura K, Iida M, Kiyohara Y: Highsensitivity C-reactive protein and coronary heart disease in a general population of Japanese: the Hisayama study. Arterioscler Thromb Vasc Biol 2008; 28: 1385-1391.
30. Yamada S, Gotoh T, Nakashima Y, Kayaba K, Ishikawa S, Nago N, Nakamura Y, Itoh Y, Kajii E: Distribution of serum C-reactive protein and its association with atherosclerotic risk factors in a Japanese population: Jichi Medical School Cohort Study. Am J Epidemiol 2001; 153: 1183-1190.
31. Woloshin S, Schwartz LM: Distribution of C-reactive protein values in the United States. N Engl J Med 2005; 352: 1611-1613.
32. Rifai N, Ridker PM: Population distributions of C-reactive protein in apparently healthy men and women in the United States: implication for clinical interpretation. Clin Chem 2003; 49: 666-669.
33. Schmidt R, Schmidt H, Curb JD, Masaki K, White LR, Launer LJ: Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging Study. Ann Neurol 2002; 52: 168-174.
34. Biasucci LM; CDC; AHA: CDC/AHA workshop on markers of inflammation and cardiovascular disease: application to clinical and public health practice: clinical use of inflammatory markers in patients with cardiovascular diseases: a background paper. Circulation 2004; 110:e560-e567.
35. Veeranna V, Zalawadiya SK, Niraj A, Kumar A, Ference B, Afonso L: Association of novel biomarkers with future cardiovascular events is influenced by ethnicity: results from a multi-ethnic cohort. Int J Cardiol 2013; 166: 487-493.
36. Singh-Manoux A, Dugravot A, Brunner E, Kumari M, Shipley M, Elbaz A, Kivimaki M: Interleukin-6 and C-reactive protein as predictors of cognitive decline in late midlife. Neurology 2014; 83: 486-493.
37. Adriaensen W, Matheï C, van Pottelbergh G, Vaes B, Legrand D, Wallemacq P, Degryse JM: Significance of serum immune markers in identification of global functional impairment in the oldest old: cross-sectional results from the BELFRAIL study. Age (Dordr) 2014; 36: 457-467.
38. Canon ME, Crimmins EM: Sex differences in the association between muscle quality, inflammatory markers, and cognitive decline. J Nutr Health Aging 2011; 15: 695-698.
39. Wersching H, Duning T, Lohmann H, Mohammadi S, Stehling C, Fobker M, Conty M, Minnerup J, Ringelstein EB, Berger K, Deppe M, Knecht S: Serum C-reactive protein is linked to cerebral microstructural integrity and cognitive function. Neurology 2010; 74: 1022-1029.
40. Roberts RO, Geda YE, Knopman DS, Boeve BF, Christianson TJH, Pankratz VS, Kullo IJ, Tangalos EG, Ivnik RJ, Petersen RC: Association of C-reactive protein with mild cognitive impairment. Alzheimers Dement 2009; 5: 398-405.
41. Kravitz BA, Corrada MM, Kawas CH: Elevated C-reactive protein levels are associated with prevalent dementia in the oldest-old. Alzheimers Dement 2009; 5: 318-323.
42. Silverman JM, Beeri MS, Schmeidler J, Rosendorff C, Angelo G, Mavris RS, Grossman HT, Elder GA, Carrion-Baralt J, West R: C-reactive protein and memory function suggest antagonistic pleiotropy in very old nondemented subjects. Age Ageing 2009; 38: 237-241.
43. Jenny NS, French B, Arnold AM, Strotmeyer ES, Cushman M, Chaves PH, Ding J, Fried LP, Kritchevsky SB, Rifkin DE, Sarnak MJ, Newman AB: Long-term assessment of inflammation and healthy aging in late life: the Cardiovascular Health Study All Stars. J Gerontol A Biol Sci Med Sci 2012; 67: 970-976.
44. Ravaglia G, Forti P, Maioli F, Chiappelli M, Montesi F, Tumini E, Mariani E, Licastro F, Patterson C: Blood inflammatory markers and risk of dementia: the Conselice Study of Brain Aging. Neurobiol Aging 2007; 28: 1810-1820.
45. Gimeno D, Marmot MG, Singh-Manoux A: Inflammatory markers and cognitive function in middle-aged adults: the Whitehall II study. Psychoneuroendocrinology 2008; 33: 1322-1334.
46. Sundelöf J, Kilander L, Helmersson J, Larsson A, Rönnemaa E, Degerman-Gunnarsson M, Basun H, Lannfelt L, Basu S: Systemic inflammation and the risk of Alzheimer's disease and dementia: a prospective populationbased study. J Alzheimers Dis 2009; 18: 79-87.
47. van Himbergen TM, Beiser AS, Ai M, Seshadri S, Otokozawa S, Au R, Thongtang N, Wolf PA, Schaefer EJ: Biomarkers for insulin resistance and inflammation and the risk for all-cause dementia and Alzheimer disease: results from the Framingham Heart Study. Arch Neurol 2012; 69: 594-600.
48. Wichmann MA, Cruickshanks KJ, Carlsson CM, Chappell R, Fischer ME, Klein BE, Klein R, Tsai MY, Schubert CR: Long-term systemic inflammation and cognitive impairment in a population-based cohort. J Am Geriatr Soc 2014; 62: 1683-1691.
49. Lima TAS, Adler AL, Minett T, Matthews FE, Brayne C, Marioni RE: C-reactive protein, APOE genotype and longitudinal cognitive change in an older population. Age Ageing 2014; 43: 289-292.
50. Gubbels Bupp MR: Sex, the aging immune system, and chronic disease. Cell Immunol 2015; 294: 102-110.
51. Fairweather D, Frisancho-Kiss S, Rose NR: Sex differences in autoimmune disease from a pathological perspective. Am J Pathol 2008; 173: 600-609.
52. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA: Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993; 261: 921-923.
53. Saunders AM, Strittmatter WJ, Schmechel D, George-Hyslop PH, Pericak-Vance MA, Joo SH, Rosi BL, Gusella JF, Crapper-MacLachlan DR, Alberts MJ, Hulette C, Crain B, Goldgaber D, Roses AD: Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993; 43: 1467-1472.
54. Strittmatter WJ, Saunders AM: Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 1993; 90: 1977-1981.
55. Judson R, Brain C, Dain B, Windemuth A, Ruaño G, Reed C: New and confirmatory evidence of an association between APOE genotype and baseline C-reactive protein in dyslipidemic individuals. Atherosclerosis 2004; 177: 345-351.
56. März W, Scharnagl H, Hoffmann MM, Boehm BO, Winkelmann BR: The apolipoprotein E polymorphism is associated with circulating C-reactive protein (the Ludwigshafen risk and cardiovascular health study). Eur Heart J 2004; 25: 2109-2119.
57. Chasman DI, Kozlowski P, Zee RY, Kwiatkowski DJ, Ridker PM: Qualitative and quantitative effects of APOE genetic variation on plasma C-reactive protein, LDL-cholesterol, and apoE protein. Genes Immun 2006; 7: 211-219.
58. Eiriksdottir G, Aspelund T, Bjarnadottir K, Olafsdottir E, Launer LJ, Harris TB: Apolipoprotein E genotype and statins affect CRP levels through independent and different mechanisms: AGES-Reykjavik Study. Atherosclerosis 2006; 186: 222-224.
59. Rontu R, Ojala P, Hervonen A, Goebeler S: Apolipoprotein E genotype is related to plasma levels of C-reactive protein and lipids and to longevity in nonagenarians. Clin Endocrinol (Oxf) 2006; 64: 265-270.
60. van Oijen M, de Maat MPM, Kardys I, de Jong FJ, Hofman A, Koudstaal PJ, Witteman JC, Breteler MM: Polymorphisms and haplotypes in the C-reactive protein gene and risk of dementia. Neurobiol Aging 2007; 28: 1361-1366.
61. Haan MN, Aiello AE, West NA, Jagust WJ: C-reactive protein and rate of dementia in carriers and non carriers of Apolipoprotein APOE4 genotype. Neurobiol Aging 2008; 29: 1774-1782.
62. Ungar L, Altmann A, Greicius MD: Apolipoprotein E, gender, and Alzheimer's disease: an overlooked, but potent and promising interaction. Brain Imaging Behav 2013; 8: 262-273.